Search

Your search keyword '"Bergman JJGHM"' showing total 7 results
Start Over Author "Bergman JJGHM" Database OAIster
7 results on '"Bergman JJGHM"'

1. 18F-FDG-PET/CT to Detect Pathological Complete Response After Neoadjuvant Treatment in Patients with Cancer of the Esophagus or Gastroesophageal Junction:Accuracy and Long-Term Implications

Author

van der Aa, D. C., Gisbertz, S. S., Anderegg, M. C.J., Lagarde, S. M., Klaassen, R., Meijer, S. L., van Dieren, S., Hulshof, Mccm, Bergman, Jjghm, Bennink, R. J., van Laarhoven, H. W.M., van Berge Henegouwen, M. I., van der Aa, D. C., Gisbertz, S. S., Anderegg, M. C.J., Lagarde, S. M., Klaassen, R., Meijer, S. L., van Dieren, S., Hulshof, Mccm, Bergman, Jjghm, Bennink, R. J., van Laarhoven, H. W.M., and van Berge Henegouwen, M. I.

Abstract

Purpose : The curative strategy for patients with esophageal cancer without distant metastases consists of esophagectomy with preceding chemo(radio)therapy (CRT). In 10–40% of patients treated with CRT, no viable tumor is detectable in the resection specimen (pathological complete response (pCR)). This study aims to define the clinical outcomes of patients with a pCR and to assess the accuracy of post-CRT FDG-PET/CT in the detection of a pCR. Methods: Four hundred sixty-three patients with cancer of the esophagus or gastroesophageal junction who underwent esophageal resection after CRT between 1994 and 2013 were included. Patients were categorized as pathological complete responders or noncomplete responders. Standardized uptake value (SUV) ratios of 135 post-CRT FDG-PET/CTs were calculated and compared with the pathological findings in the corresponding resection specimens. Results: Of the 463 included patients, 85 (18.4%) patients had a pCR. During follow-up, 25 (29.4%) of these 85 patients developed recurrent disease. Both 5-year disease-free survival (5y-DFS) and 5-year overall survival (5y-OS) were significantly higher in complete responders compared to noncomplete responders (5y-DFS 69.6% vs. 44.2%; P = 0.001 and 5y-OS 66.5% vs. 43.7%; P = 0.001). Not pCR, but only pN0 was identified as an independent predictor of (disease-free) survival. Conclusion: Patients with a pCR have a higher probability of survival compared to noncomplete responders. One third of patients with a pCR do develop recurrent disease, and pCR can therefore not be equated with cure. FDG-PET/CT was inaccurate to predict pCR and therefore cannot be used as a sole diagnostic tool to predict pCR after CRT for esophageal cancer.

Published
2024

2. Endoscopic Resection Without Subsequent Ablation Therapy for Early Barrett’s Neoplasia: Endoscopic Findings and Long-Term Mortality

Author

van Munster, SN, Nieuwenhuis, EA, Weusten, BLAM, Herrero, LA, Bogte, A, Alkhalaf, A, Schenk, BE, Schoon, EJ, Curvers, W, Koch, Arjun, van de Ven, Steffi, de Jonge, Pieter Jan, Tang, T, Nagengast, WB, Peters, FT, Westerhof, J, Houben, MHMG, Bergman, JJGHM, Pouw, RE, van Munster, SN, Nieuwenhuis, EA, Weusten, BLAM, Herrero, LA, Bogte, A, Alkhalaf, A, Schenk, BE, Schoon, EJ, Curvers, W, Koch, Arjun, van de Ven, Steffi, de Jonge, Pieter Jan, Tang, T, Nagengast, WB, Peters, FT, Westerhof, J, Houben, MHMG, Bergman, JJGHM, and Pouw, RE

Abstract

Introduction: After endoscopic resection (ER) of neoplasia in Barrett’s esophagus (BE), it is recommended to ablate the remaining BE to minimize the risk for metachronous disease. However, we report long-term outcomes for a nationwide cohort of all patients who did not undergo ablation of the remaining BE after ER for early BE neoplasia, due to clinical reasons or performance status. Methods: Endoscopic therapy for BE neoplasia in the Netherlands is centralized in 8 expert centers with specifically trained endoscopists and pathologists. Uniformity is ensured by a joint protocol and regular group meetings. We report all patients who underwent ER for a neoplastic lesion between 2008 and 2018, without further ablation therapy. Outcomes include progression during endoscopic FU and all-cause mortality. Results: Ninety-four patients were included with mean age 74 (± 10) years. ER was performed for low-grade dysplasia (LGD) (10%), high-grade dysplasia (HGD) (25%), or low-risk esophageal adenocarcinoma (EAC) (65%). No additional ablation was performed for several reasons; in 73 patients (78%), the main argument was expected limited life expectancy. Median C2M5 BE persisted after ER, and during median 21 months (IQR 11–51) with 4 endoscopies per patient, no patient progressed to advanced cancer. Seventeen patients (18%) developed HGD/EAC: all were curatively treated endoscopically. In total, 29/73 patients (40%) with expected limited life expectancy died due to unrelated causes during FU, none of EAC. Conclusion: In selected patients, ER monotherapy with endoscopic surveillance of the residual BE is a valid alternative to eradication therapy with ablation.

Published
2021

3. Adherence to pre-set benchmark quality criteria to qualify as expert assessor of dysplasia in Barrett's esophagus biopsies - towards digital review of Barrett's esophagus

Author

van der Wel, M J, Klaver, E, Duits, L C, Pouw, R E, Seldenrijk, C A, Offerhaus, Gja, Visser, M, Ten Kate, Fjw, Biermann, K, Brosens, Laa, Doukas, M, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J S, van Lijnschoten, G, Moll, Fcp, Ooms, Ahag, Tijssen, J G, Bergman, Jjghm, Meijer, S L, van der Wel, M J, Klaver, E, Duits, L C, Pouw, R E, Seldenrijk, C A, Offerhaus, Gja, Visser, M, Ten Kate, Fjw, Biermann, K, Brosens, Laa, Doukas, M, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J S, van Lijnschoten, G, Moll, Fcp, Ooms, Ahag, Tijssen, J G, Bergman, Jjghm, and Meijer, S L

Published
2019

4. Adherence to pre-set benchmark quality criteria to qualify as expert assessor of dysplasia in Barrett's esophagus biopsies - towards digital review of Barrett's esophagus

Author

van der Wel, M J, Klaver, E, Duits, L C, Pouw, R E, Seldenrijk, C A, Offerhaus, Gja, Visser, M, Ten Kate, Fjw, Biermann, K, Brosens, Laa, Doukas, M, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J S, van Lijnschoten, G, Moll, Fcp, Ooms, Ahag, Tijssen, J G, Bergman, Jjghm, Meijer, S L, van der Wel, M J, Klaver, E, Duits, L C, Pouw, R E, Seldenrijk, C A, Offerhaus, Gja, Visser, M, Ten Kate, Fjw, Biermann, K, Brosens, Laa, Doukas, M, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J S, van Lijnschoten, G, Moll, Fcp, Ooms, Ahag, Tijssen, J G, Bergman, Jjghm, and Meijer, S L

Published
2019

5. Adherence to pre-set benchmark quality criteria to qualify as expert assessor of dysplasia in Barrett's esophagus biopsies - towards digital review of Barrett's esophagus

Author

van der Wel, M J, Klaver, E, Duits, L C, Pouw, R E, Seldenrijk, C A, Offerhaus, Gja, Visser, M, Ten Kate, Fjw, Biermann, K, Brosens, Laa, Doukas, M, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J S, van Lijnschoten, G, Moll, Fcp, Ooms, Ahag, Tijssen, J G, Bergman, Jjghm, Meijer, S L, van der Wel, M J, Klaver, E, Duits, L C, Pouw, R E, Seldenrijk, C A, Offerhaus, Gja, Visser, M, Ten Kate, Fjw, Biermann, K, Brosens, Laa, Doukas, M, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J S, van Lijnschoten, G, Moll, Fcp, Ooms, Ahag, Tijssen, J G, Bergman, Jjghm, and Meijer, S L

Published
2019

6. Adherence to pre-set benchmark quality criteria to qualify as expert assessor of dysplasia in Barrett's esophagus biopsies - towards digital review of Barrett's esophagus

Author

MS CGO, Pathologie Pathologen staf, Cancer, van der Wel, M J, Klaver, E, Duits, L C, Pouw, R E, Seldenrijk, C A, Offerhaus, Gja, Visser, M, Ten Kate, Fjw, Biermann, K, Brosens, Laa, Doukas, M, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J S, van Lijnschoten, G, Moll, Fcp, Ooms, Ahag, Tijssen, J G, Bergman, Jjghm, Meijer, S L, MS CGO, Pathologie Pathologen staf, Cancer, van der Wel, M J, Klaver, E, Duits, L C, Pouw, R E, Seldenrijk, C A, Offerhaus, Gja, Visser, M, Ten Kate, Fjw, Biermann, K, Brosens, Laa, Doukas, M, Huysentruyt, C, Karrenbeld, A, Kats-Ugurlu, G, van der Laan, J S, van Lijnschoten, G, Moll, Fcp, Ooms, Ahag, Tijssen, J G, Bergman, Jjghm, and Meijer, S L

Published
2019

7. Forward-viewing versus oblique-viewing echoendoscopes in transluminal drainage of pancreatic fluid collections: a multicenter, randomized, controlled trial

Author

Voermans, Rp, Ponchon, T, Schumacher, B, Fumex, F, Bergman, Jjghm, Larghi, Alberto, Neuhaus, H, Costamagna, Guido, Fockens, P., Costamagna, Guido (ORCID:0000-0002-8100-2731), Voermans, Rp, Ponchon, T, Schumacher, B, Fumex, F, Bergman, Jjghm, Larghi, Alberto, Neuhaus, H, Costamagna, Guido, Fockens, P., and Costamagna, Guido (ORCID:0000-0002-8100-2731)

Abstract

EUS-guided drainage of pancreatic fluid collections (PFCs) is commonly performed with oblique-viewing echoendoscopes. However, accessing the PFC under an oblique angle can make drainage difficult. These difficulties might be overcome by using a forward-viewing echoendoscope.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results